Literature DB >> 12381683

Involvement of tissue kallikrein but not plasma kallikrein in the development of symptoms mediated by endogenous kinins in acute pancreatitis in rats.

Thomas Griesbacher1, Irmgard Rainer, Beate Tiran, D Michael Evans.   

Abstract

In order to investigate the mechanism of kinin release leading to vascular symptoms in acute interstitial-oedematous pancreatitis, the novel, selective inhibitors of tissue kallikrein, (2S,2'R)-2-(2'-amino-3'-(4'-chlorophenyl)propanoylamino)-N-(3-guanidinopropyl)-3-(1-naphthyl)propanoamide (FE999024, CH-2856), and of plasma kallikrein, (2'S,2"R)-4-(2'-(2"(carboxymethylamino)-3"-cyclohexyl-propanoylamino)-3'-phenyl-propanoylamino)piperidine-1-carboxamidin (FE999026, CH-4215), were used in experimental caerulein-induced pancreatitis in rats. Oedema formation and plasma protein extravasation during the 2 h infusion of caerulein were inhibited in a dose-dependent manner by i.p. pretreatment with FE999024 (7-60 micromol kg(-1)) while FE999026 had no effect at the same doses. Haemoconcentration and hypovolaemia associated with the pancreatic oedema formation during pancreatitis were significantly attenuated by FE999024 at a dose of 20 micro mol kg(-1). The reduction in circulating plasma volume was not affected by FE999026. Accumulation of amylase and lipase in the pancreas was dose-dependently reduced by FE999024 while enzyme activities in the blood serum were increased by FE999024 at 60 micromol kg(-1) indicating improved enzyme removal from the tissue. Enzyme activities in the tissue and in the blood remained unaffected by FE999026. FE999024 (20 micromol kg(-1)) largely inhibited increased tissue kallikrein-like activity in the pancreas during acute pancreatitis and also strongly attenuated influx of plasma kallikrein into the tissue. FE999026 (20 micromol kg(-1)) significantly inhibited plasma kallikrein-like activity in the pancreas but had no effect on tissue kallikrein-like activity. In conclusion, vascular kinin-mediated symptoms observed during oedematous pancreatitis in the rat are caused by the action of tissue kallikrein in the pancreas whereas an involvement of plasma kallikrein seems to be unlikely.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12381683      PMCID: PMC1573532          DOI: 10.1038/sj.bjp.0704910

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  27 in total

1.  [The problem of therapy of pancreatitis].

Authors:  E WERLE; K TAUBER; W HARTENBACH; M M FORELL
Journal:  Munch Med Wochenschr       Date:  1958-08-29

2.  Blockade of bradykinin B(2) receptor suppresses acute pancreatitis induced by obstruction of the pancreaticobiliary duct in rats.

Authors:  Mitsuhiro Hirata; Izumi Hayashi; Kuniko Yoshimura; Ken-ichiro Ishii; Kazui Soma; Takashi Ohwada; Akira Kakita; Masataka Majima
Journal:  Br J Pharmacol       Date:  2002-01       Impact factor: 8.739

Review 3.  Hormone-induced pancreatitis.

Authors:  S Willemer; H P Elsässer; G Adler
Journal:  Eur Surg Res       Date:  1992       Impact factor: 1.745

4.  Acute pancreatitis: a lethal disease of increasing incidence.

Authors:  A P Corfield; M J Cooper; R C Williamson
Journal:  Gut       Date:  1985-07       Impact factor: 23.059

5.  Effects of the bradykinin antagonist, HOE 140, in experimental acute pancreatitis.

Authors:  T Griesbacher; F Lembeck
Journal:  Br J Pharmacol       Date:  1992-10       Impact factor: 8.739

6.  The bradykinin antagonist CP-0597 can limit the progression of postischemic pancreatitis.

Authors:  T F Hoffmann; H Waldner; K Messmer
Journal:  Immunopharmacology       Date:  1996-06

7.  Pathological events in experimental acute pancreatitis prevented by the bradykinin antagonist, Hoe 140.

Authors:  T Griesbacher; B Tiran; F Lembeck
Journal:  Br J Pharmacol       Date:  1993-02       Impact factor: 8.739

8.  Synthetic inhibitors of human tissue kallikrein.

Authors:  D M Evans; D M Jones; G R Pitt; D Ashworth; F De Clerck; F Verheyen; M Szelke
Journal:  Immunopharmacology       Date:  1996-05

9.  Selective inhibitors of plasma kallikrein.

Authors:  D M Evans; D M Jones; G R Pitt; J Sueiras-Diaz; J Horton; D Ashworth; H Olsson; M Szelke
Journal:  Immunopharmacology       Date:  1996-05

10.  Acute interstitial pancreatitis in the rat induced by excessive doses of a pancreatic secretagogue.

Authors:  M Lampel; H F Kern
Journal:  Virchows Arch A Pathol Anat Histol       Date:  1977-03-11
View more
  6 in total

1.  Ascitic fluid and serum from rats with acute pancreatitis injure rat pancreatic tissues and alter the expression of heat shock protein 60.

Authors:  Yong-Yu Li; Xue-Jin Li; Shuai Lv; Kun Li; Yan-Na Li; Zhi-Rong Gao; Jia-Yan Feng; Chang-Jie Chen; Claus Schaefer
Journal:  Cell Stress Chaperones       Date:  2010-02-10       Impact factor: 3.667

Review 2.  Gastrointestinal roles for proteinase-activated receptors in health and disease.

Authors:  A Kawabata; M Matsunami; F Sekiguchi
Journal:  Br J Pharmacol       Date:  2007-11-12       Impact factor: 8.739

3.  Neutrophils and the kallikrein-kinin system in proteinase-activated receptor 4-mediated inflammation in rodents.

Authors:  Steeve Houle; Martin D Papez; Mara Ferazzini; Morley D Hollenberg; Nathalie Vergnolle
Journal:  Br J Pharmacol       Date:  2005-11       Impact factor: 8.739

4.  Kallikrein inhibitors limit kinin B(2) antagonist-induced progression of oedematous to haemorrhagic pancreatitis in rats.

Authors:  T Griesbacher; I Rainer; B Tiran; B A Peskar
Journal:  Br J Pharmacol       Date:  2008-08-11       Impact factor: 8.739

5.  Mechanism of kinin release during experimental acute pancreatitis in rats: evidence for pro- as well as anti-inflammatory roles of oedema formation.

Authors:  Thomas Griesbacher; Irmgard Rainer; Beate Tiran; Edwin Fink; Fred Lembeck; Bernhard A Peskar
Journal:  Br J Pharmacol       Date:  2003-05       Impact factor: 8.739

6.  Tissue Kallikrein Exacerbating Sepsis-Induced Endothelial Hyperpermeability is Highly Predictive of Severity and Mortality in Sepsis.

Authors:  Xiao Ran; Qin Zhang; Shaoping Li; Zhen Yu; Li Wan; Bin Wu; Rongxue Wu; Shusheng Li
Journal:  J Inflamm Res       Date:  2021-07-15
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.